Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTreme: Neoadjuvant Gemcitabine/Cisplatin Plus Durvalumab and Tremelimumab in Intrahepatic Cholangiocarcinoma
DRKS00032093Phase 2Active, not recruiting
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Jun 2023
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of gemcitabine, cisplatin, durvalumab and tremelimumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Universitätsklinikum Schleswig-Holstein. Started Jun 2023; status: active, not recruiting.
02
Drugs
gemcitabinecisplatindurvalumabtremelimumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on DRKS00032093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00032093.